Latest Articles
AstraZeneca’s ENHERTU Enters Pivotal Phase 3 Trial for Endometrial Cancer - MSN
AstraZeneca’s ENHERTU Enters Pivotal Phase 3 Trial for Endometrial Cancer MSN
Published: June 16, 2025, 11:46 a.m.
AstraZeneca’s ENHERTU Enters Pivotal Phase 3 Trial for Endometrial Cancer - Insider Monkey
AstraZeneca’s ENHERTU Enters Pivotal Phase 3 Trial for Endometrial Cancer Insider Monkey
Published: June 15, 2025, 9:42 a.m.
AstraZeneca’s ENHERTU Enters Pivotal Phase 3 Trial for Endometrial Cancer - Yahoo
AstraZeneca’s ENHERTU Enters Pivotal Phase 3 Trial for Endometrial Cancer Yahoo
Published: June 15, 2025, 9:39 a.m.
S2 Episode 6: Sequencing Antibody-Drug Conjugates in Endometrial Cancer - Medscape
S2 Episode 6: Sequencing Antibody-Drug Conjugates in Endometrial Cancer Medscape
Published: June 12, 2025, 1:50 p.m.
Daiichi announces first subject dosing in Enhertu trial for endometrial cancer - Yahoo
Daiichi announces first subject dosing in Enhertu trial for endometrial cancer Yahoo
Published: June 10, 2025, 9:47 a.m.
Daiichi announces first subject dosing in Enhertu trial for endometrial cancer - Clinical Trials Arena
Daiichi announces first subject dosing in Enhertu trial for endometrial cancer Clinical Trials Arena
Published: June 10, 2025, 9:06 a.m.
Dostarlimab + Chemo Beneficial for Advanced, Recurrent Endometrial Cancer - Physician's Weekly
Dostarlimab + Chemo Beneficial for Advanced, Recurrent Endometrial Cancer Physician's Weekly
Published: June 10, 2025, 6:31 a.m.
Dostarlimab + Chemo Beneficial for Advanced, Recurrent Endometrial Cancer - HealthDay
Dostarlimab + Chemo Beneficial for Advanced, Recurrent Endometrial Cancer HealthDay
Published: June 9, 2025, 2:50 p.m.
AZN Initiates Phase 3 Trial for Enhertu in Advanced Endometrial Cancer | AZN Stock News - GuruFocus
AZN Initiates Phase 3 Trial for Enhertu in Advanced Endometrial Cancer | AZN Stock News GuruFocus
Published: June 9, 2025, 12:46 p.m.
DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer - BioSpace
DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer BioSpace
Published: June 9, 2025, 12:43 p.m.
Link copied to clipboard!